New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:00 EDTINCYIncyte ruxolitinib data 'a home run, ' says Oppenheimer
After Incyte reported results from a Phase III study of its ruxolitinib in polycythemia vera, Oppenheimer expects the drug to be approved and generate significant commercial sales. The firm keeps a $75 price target and Outperform rating on the stock.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
08:10 EDTINCYIncyte price target raised to $115 from $90 at Leerink
Subscribe for More Information
April 30, 2015
12:43 EDTINCYIncyte price target raised to $107 from $84 at Brean Capital
Subscribe for More Information
09:06 EDTINCYIncyte receives orphan status for Hodgkin lymphoma treatment
Subscribe for More Information
07:19 EDTINCYIncyte reports Q1 EPS (11c) consensus (10c)
Reports Q1 revenue $159.3M, consensus $155.21M.
April 21, 2015
05:57 EDTINCYIncyte price target raised to $121 from $80 at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use